CAPR CAPRICOR THERAP

3.23
+0  (5%)
Previous Close 3.09
Open 3.45
Price To book 0.00
Market Cap 69.12M
Shares 21,399,000
Volume 3,241,744
Short Ratio 2.04
Av. Daily Volume 120,145

SEC filingsSee all SEC filings

  1. 8-K - Current report 17781735
  2. 8-K - Current report 17779615
  3. DEF 14A - Other definitive proxy statements 17774153
  4. 424B5 - Prospectus (Rule 424(b)(5)) 17732122
  5. 424B5 - Prospectus (Rule 424(b)(5)) 17731134

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 completed. Waiting on data from additional study to determine future
Cenderitide
Ambulatory heart failure
Phase 1/2 data released April 25, 2017. Noted improvement in certain measures of cardiac and upper limb function. 12-month data due 4Q 2017.
CAP-1002 HOPE-Duchenne
Duchenne Muscular Dystrophy (DMD)
Phase 2 enrolling. 6 month data likely due 2Q 2017.
CAP-1002 ALLSTAR
Myocardial infarction (heart attack)

Latest News

  1. Blog Coverage Capricor Announces Positive Results from Trial for the Treatment of Duchenne Muscular Dystrophy
  2. Capricor Therapeutics to Present at the Alliance for Regenerative Medicine's Cell & Gene Therapy Investor Day
  3. ETFs with exposure to Capricor Therapeutics, Inc. : April 25, 2017
  4. Capricor Therapeutics Stock Surging on Positive Muscular Dystrophy Trial Results
  5. Capricor Therapeutics Announces Positive Six-Month Results from the Randomized Phase I/II HOPE Clinical Trial in Duchenne Muscular Dystrophy
  6. Capricor Therapeutics to Report Six-Month Results from the Randomized Phase I/II HOPE Clinical Trial in Duchenne Muscular Dystrophy
  7. Rockwell Medical (RMTI) Looks Good: Stock Moves 5.9% Higher
  8. Capricor Therapeutics, Inc. :CAPR-US: Earnings Analysis: Q4, 2016 By the Numbers : March 21, 2017
  9. Capricor reports 4Q loss
  10. Capricor Therapeutics Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Corporate Update
  11. Investor Network Invites You to the Capricor Therapeutics Fourth Quarter and Full Year 2016 Business Update and Financial Results Conference Call and Webcast on Wednesday, March 15, 2017
  12. Capricor Therapeutics to Hold Fourth Quarter and Full Year 2016 Financial Results and Corporate Update Conference Call on Wednesday, March 15
  13. Capricor Therapeutics to Present at Two Investor Conferences in March
  14. Capricor Therapeutics Ends Heart Drug Development
  15. Capricor Therapeutics Provides Update on Natriuretic Peptide Program
  16. Capricor Therapeutics to Present at the 2017 BIO CEO and Investor Conference
  17. ETFs with exposure to Capricor Therapeutics, Inc. : December 13, 2016
  18. Capricor Therapeutics to Present at the 28th Annual Piper Jaffray Healthcare Conference
  19. Capricor Therapeutics Reports Third Quarter 2016 Financial Results and Provides Corporate Update

SEC Filings

  1. 8-K - Current report 17781735
  2. 8-K - Current report 17779615
  3. DEF 14A - Other definitive proxy statements 17774153
  4. 424B5 - Prospectus (Rule 424(b)(5)) 17732122
  5. 424B5 - Prospectus (Rule 424(b)(5)) 17731134
  6. 8-K - Current report 17731118
  7. 10-K - Annual report (Section 13 and 15(d), not S-K Item 405) 17692780
  8. 8-K - Current report 17691437
  9. 8-K - Current report 17618685
  10. 8-K - Current report 17614263